Media Articles Related to Sulfamylon (Mafenide Topical)
How to stop pain from serious burns using epigenetics
Source: Pain / Anesthetics News From Medical News Today [2017.02.02]
The unpleasant sensation sparked by the nervous system when confronted with a harmful stimulus can be alleviated by blocking a genetic marker that switches off the activity of the neurons involved.
Burns (First Aid)
Source: MedicineNet Hyperkalemia Specialty [2016.08.25]
Title: Burns (First Aid)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/25/2016 12:00:00 AM
Sun-Damaged Skin: Pictures of Sun Spots, Wrinkles, Sunburns
Source: MedicineNet Actinic Keratosis Specialty [2016.06.06]
Title: Sun-Damaged Skin: Pictures of Sun Spots, Wrinkles, Sunburns
Created: 6/11/2008 12:00:00 AM
Last Editorial Review: 6/6/2016 12:00:00 AM
Large increase in eye injuries linked to laundry detergent pods among young children
Source: Eye Health / Blindness News From Medical News Today [2017.02.06]
Between 2012 and 2015, the number of chemical burns to the eye associated with laundry detergent pods increased more than 30-fold among preschool-aged children in the U.S.
Burn Risk Seen with Topical Pain Relievers
Source: MedPage Today Product Alert [2012.09.13]
WASHINGTON -- The FDA warned Thursday of the risks of rare but serious chemical burns with certain over-the-counter topical pain relievers, including Bengay, Capzasin, Flexall, Icy Hot, and Mentholatum.
Published Studies Related to Sulfamylon (Mafenide Topical)
Systemic absorption of amphotericin B with topical 5% mafenide acetate/amphotericin B solution for grafted burn wounds: is it clinically relevant? [2010.02]
OBJECTIVE: To determine if patients receiving topical amphotericin B in combination with 5% mafenide acetate solution will acquire systemically detectable levels of amphotericin B... CONCLUSIONS: We conclude that 5% mafenide acetate/amphotericin B (2 mcg/ml) solution, applied to excised and grafted burn wounds, does not produce clinically relevant serum levels of amphotericin B. Based on our observations, this topical regimen is safe. Copyright (c) 2009 Elsevier Ltd and ISBI. All rights reserved.
Allergic contact dermatitis to mafenide acetate: a case series and review of the literature. [2007.08]
Burn patients with extensive involvement of body surface area (BSA >30%) represent a challenge in wound treatment. Multiple topical agents may be used for cleansing, barrier protection, and antimicrobial control leading to complications of contact and/or irritant dermatitis, which may further complicate re-epithelization and eventual wound healing...
Topical Sulfamylon cream inhibits DNA and protein synthesis in the skin donor site wound. [2006.05]
BACKGROUND: Whereas Sulfamylon is effective in treatment of burn wound infection, controversy exists regarding its effect on the healing process... CONCLUSIONS: Topical Sulfamylon cream application inhibited DNA and protein synthesis in the wound, which would be expected to retard the healing process.
Mafenide acetate allergy presenting as recurrent chondritis. [2002.02]
Acute chondritis has a strong predilection for recurrence. Mafenide acetate has been implicated in causing reactions that mimic this condition; however, these hypersensitivity reactions lack fever, fluctuance, and pain... Therefore, auricular edema and erythema, without fever, fluctuance, and pain, must be recognized by surgeons as a possible mafenide acetate allergy and must be considered in the differential diagnosis for patients who present with recurrent acute suppurative chondritis.
Off-label drug use in WOC nursing: issues related to use of mafenide acetate to treat infected chronic wounds. [2001.09]
It is not unusual for practitioners to prescribe off-label drugs for their patients--that is, drugs that have not yet been approved by the Food and Drug Administration to treat the patient's particular condition... This article presents the issues related to off-label use of mafenide acetate (Sulfamylon) and possible implications for patients with chronic infected wounds.
Clinical Trials Related to Sulfamylon (Mafenide Topical)
Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon« For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group [Completed]
The primary objective is to compare the effectiveness of treatment with Sulfamylon« solution
as the initial topical moist dressing over meshed autografts following the initial graft
procedure on preventing graft loss in a prospective cohort of subjects versus a historical
control group in a non-inferiority trial.
Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks [Terminated]
Determine effectiveness of various antimicrobial solutions on burn wounds (infections, wound
healing, length of hospital stay).
Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.
Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns [Active, not recruiting]
The purpose of this study is to evaluate the P6 Low Adherent Study Dressing relative to the
Standard of Care (SOC, Mafenide Acetate 5% Solution) for the management of skin grafts in
burn wounds resulting from thermal burn injuries.